US Supreme Court allows cholesterol drug suit

Jun 16, 2011

The US Supreme Court on Thursday allowed a class-action suit by alleged victims of the anti-cholesterol drug Baycol, which was taken off the market in 2001 by German pharmaceuticals giant Bayer.

The top US court said in a unanimous decision that lower courts were not allowed to ban class-action suits for the drug, which went on the US market in 1997 and was blamed for the deaths of 31 Americans four years later due to side effects, including fatal muscle toxicity leading to kidney failure.

Several legal cases were lodged over the drug, also known by its chemical name cerivastatin.

The suits were put together in a federal court in Minnesota, but in the case delivered to the high court, the plaintiffs were from West Virginia.

Bayer, which had argued that the class-action suit could not proceed because the judge in charge of cases in Minnesota banned such suits back in August 2005, expressed disappointment with the decision.

"Bayer is disappointed by today's ruling, which overturns a decision by the US Court of Appeals for the Eighth Circuit that upheld a decision to prevent the proposed state economic loss class action lawsuit from moving forward," the company said in a statement.

Bayer will continue to defend this case, including on the issue of class certification, should it move forward at the state level," the company statement said.

But the Supreme Court reversed the Eighth Circuit's decision to issue an injuction that had banned a class-action suit, saying "the federal court exceeded its authority under the 're-litigation exception.'"

Bayer voluntarily recalled the drug in August 2001 after 31 deaths due to rhabdomyolysis, a breakdown of muscle tissue.

Baycol, part of the class of cholesterol-lowering drugs known as statins, was first approved by the US Food and Drug Administration in 1997.

Explore further: FDA approves hard-to-abuse narcotic painkiller

add to favorites email to friend print save as pdf

Related Stories

Court won't stop hormone replacement lawsuits

Oct 12, 2010

(AP) -- The Supreme Court won't reconsider a decision to reinstate more than 100 lawsuits filed by women who claimed that hormone replacement therapy caused breast cancer.

Court Denies Vonage Bid for Patent Case Retrial

May 04, 2007

A U.S. appeals court denies a request by Internet phone company Vonage Holdings that it order a retrial in the patent infringement case brought against it by Verizon Communications.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments : 0